Trial · NCT03799627
Results by group597
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 597
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Baseline | 10.223 | Standard Deviation 0.5805 | grams per deciliter (g/dL) |
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Baseline | 10.059 | Standard Deviation 0.6769 | grams per deciliter (g/dL) |
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | Low Dose of Epoetin Alfa: Epoetin Alfa | Baseline | 10.165 | Standard Deviation 0.6806 | grams per deciliter (g/dL) |
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | High Dose of Epoetin Alfa: Vadadustat 300 mg | Baseline | 9.778 | Standard Deviation 0.6832 | grams per deciliter (g/dL) |
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | High Dose of Epoetin Alfa: Vadadustat 450 mg | Baseline | 10.288 | Standard Deviation 0.5445 | grams per deciliter (g/dL) |
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | High Dose of Epoetin Alfa: Vadadustat 600 mg | Baseline | 10.095 | Standard Deviation 0.7150 | grams per deciliter (g/dL) |
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | High Dose of Epoetin Alfa: Epoetin Alfa | Baseline | 9.950 | Standard Deviation 0.7950 | grams per deciliter (g/dL) |
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | ESA Hyporesponder: Vadadustat 600 mg | Baseline | 9.530 | Standard Deviation 0.2864 | grams per deciliter (g/dL) |
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | ESA Hyporesponder: Epoetin Alfa | Baseline | 9.620 | Standard Deviation 0.6925 | grams per deciliter (g/dL) |
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Change from Baseline at PEP | -0.371 | Standard Deviation 0.8920 | grams per deciliter (g/dL) |
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Change from Baseline at PEP | 0.072 | Standard Deviation 1.1353 | grams per deciliter (g/dL) |
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | Low Dose of Epoetin Alfa: Epoetin Alfa | Change from Baseline at PEP | 0.160 | Standard Deviation 0.7519 | grams per deciliter (g/dL) |
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | High Dose of Epoetin Alfa: Vadadustat 300 mg | Change from Baseline at PEP | -0.911 | Standard Deviation 1.3515 | grams per deciliter (g/dL) |
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | High Dose of Epoetin Alfa: Vadadustat 450 mg | Change from Baseline at PEP | -0.284 | Standard Deviation 1.0383 | grams per deciliter (g/dL) |
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | High Dose of Epoetin Alfa: Vadadustat 600 mg | Change from Baseline at PEP | -0.418 | Standard Deviation 1.2752 | grams per deciliter (g/dL) |
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | High Dose of Epoetin Alfa: Epoetin Alfa | Change from Baseline at PEP | 0.268 | Standard Deviation 1.0087 | grams per deciliter (g/dL) |
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | ESA Hyporesponder: Vadadustat 600 mg | Change from Baseline at PEP | -0.671 | Standard Deviation 0.7643 | grams per deciliter (g/dL) |
| Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP) | ESA Hyporesponder: Epoetin Alfa | Change from Baseline at PEP | -0.290 | Standard Deviation 1.7730 | grams per deciliter (g/dL) |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Low Dose of Epoetin Alfa: Vadadustat 300 mg | 18 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Low Dose of Epoetin Alfa: Vadadustat 450 mg | 27 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03799627/results